- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Osteonectin antibody, also known as SPARC antibody, recognizes Secreted protein acidic and rich in cysteine, a matricellular glycoprotein that regulates extracellular matrix organization and cell-matrix interactions. The human SPARC gene is located on chromosome 5q33.1 and encodes a secreted protein that localizes to the extracellular space and basement membranes. Secreted protein acidic and rich in cysteine is a member of the SPARC family of matricellular proteins and is widely referred to in the literature as Osteonectin and BM-40.
Secreted protein acidic and rich in cysteine plays a central role in modulating cell adhesion, migration, and proliferation through its effects on the extracellular matrix. It is highly expressed in bone, connective tissue, endothelial cells, and remodeling stroma. In skeletal biology, Osteonectin is abundant in osteoblasts and bone matrix, where it contributes to collagen organization and mineralization. An Osteonectin antibody is frequently used in studies focused on tumor stroma, fibrosis, angiogenesis, and tissue repair because SPARC influences matrix composition and growth factor signaling.
The SPARC protein contains an acidic N-terminal region, a follistatin-like domain, and a C-terminal extracellular calcium-binding domain with EF-hand motifs. These structural features enable calcium binding and facilitate interactions with collagens, albumin, and other matrix-associated proteins. Through these interactions, Secreted protein acidic and rich in cysteine participates in pathways such as TGF-beta signaling and integrin-mediated adhesion cascades, contributing to extracellular matrix remodeling and vascular responses.
In oncology research, SPARC expression is commonly associated with activated fibroblasts and desmoplastic stroma in tumors including breast, pancreatic, colorectal, and ovarian carcinomas. Depending on tumor type and microenvironment, SPARC may influence tumor progression, invasion, or stromal remodeling. Outside of cancer, SPARC is upregulated during wound healing and in fibrotic diseases affecting liver, lung, and kidney, where it supports collagen deposition and matrix reorganization. Developmentally, expression is observed during embryogenesis in tissues undergoing active morphogenesis and vascular development.
Clone rOSTN/8527 is a recombinant monoclonal antibody developed to recognize SPARC in research applications. An Osteonectin antibody supports investigation of extracellular matrix biology, stromal activation, and connective tissue remodeling. This antibody targets SPARC in research settings and is suitable for studies of fibrosis, angiogenesis, skeletal biology, and tumor-associated stromal dynamics.
Optimal dilution of the Osteonectin antibody should be determined by the researcher.
A recombinant partial protein sequence (within amino acids 1-200) from the human protein was used as the immunogen for the Osteonectin antibody.
Aliquot the Osteonectin antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.